Loading…

Medical Research Finder

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

Mitogen-activated protein kinases (MAPKs or MAP kinases) inhibitors & Melanoma (cutaneous)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

In cutaneous melanoma, Mitogen-activated protein kinases (MAPKs or MAP kinases) inhibitors in practice mostly means BRAF and MEK inhibitors targeting the ERK/MAPK pathway, with some emerging work on ERK, NRAS, and upstream nodes
Inamdar et al. 2010 Biochem Pharmacol 80(5): 624-37
Wellbrock & Arozarena 2016 Front Cell Dev Biol 4: 33
Caksa et al. 2022 Pharmacology & Therapeutics 239: 108200

see also:
[Melanoma (cutaneous) (BRAF m) & Drugs/Treatments](brain://Px7daOC2-0SLrwC74JjNEg/MelanomaCutaneousBrafMDrugsTreatme…

MAPK blockade, toxicities, pathogenesis and management
Moreira et al. 2021 Current Opinion in Oncology 33: 139-145
Mitogen-activated protein kinase blockade in melanoma: intermittent versus continuous therapy, from preclinical to clinical data
Tétu et al. 2021 Current Opinion in Oncology 33: 127-132
Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail
Inamdar et al. 2010 Biochem Pharmacol 80(5): 624-37
The Complexity of the ERK/MAP-Kinase Pathway and the Treatment of Melanoma Skin Cancer
Wellbrock & Arozarena 2016 Front Cell Dev Biol 4: 33
Review
The future of targeted kinase inhibitors in melanoma
Caksa et al. 2022 Pharmacology & Therapeutics 239: 108200
Review

7/1/2026